Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
July 31, 2026 46.99M
April 30, 2026 46.71M
January 31, 2026 46.71M
October 31, 2025 46.16M
July 31, 2025 46.15M
April 30, 2025 46.15M
January 31, 2025 45.77M
October 31, 2024 30.29M
July 31, 2024 27.30M
April 30, 2024 26.94M
January 31, 2024 26.32M
October 31, 2023 25.05M
July 31, 2023 25.05M
April 30, 2023 25.05M
January 31, 2023 24.97M
October 31, 2022 24.94M
July 31, 2022 24.84M
April 30, 2022 24.48M
January 31, 2022 19.46M
October 31, 2021 19.37M
July 31, 2021 19.27M
April 30, 2021 19.17M
January 31, 2021 17.12M
October 31, 2020 16.76M
July 31, 2020 14.81M
Date Value
April 30, 2020 13.98M
January 31, 2020 13.60M
October 31, 2019 13.60M
July 31, 2019 13.60M
April 30, 2019 13.59M
January 31, 2019 13.44M
October 31, 2018 13.42M
July 31, 2018 11.29M
April 30, 2018 11.09M
January 31, 2018 9.529M
October 31, 2017 9.429M
July 31, 2017 7.716M
April 30, 2017 7.716M
January 31, 2017 7.552M
December 31, 2015 0.5501M
September 30, 2015 0.5501M
June 30, 2015 0.5501M
March 31, 2015 0.5501M
December 31, 2014 0.5501M
September 30, 2014 0.5501M
June 30, 2014 0.5501M
March 31, 2014 0.5501M
December 31, 2013 0.5501M
September 30, 2013 0.5501M
June 30, 2013 0.5501M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Repligen Corp. 56.43M
Bio-Techne Corp. 156.10M
BioLife Solutions, Inc. 48.89M
Maravai Lifesciences Holdings, Inc. 148.89M
MaxCyte, Inc. 106.13M